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Abstract
Cryptococcosis remains the leading cause of fungal meningitis worldwide, caused primarily
by the pathogen Cryptococcus neoformans. Symptomatic cryptococcal infections typically
affect immunocompromised patients. However, environmental exposure to cryptococcal
spores is ubiquitous and most healthy individuals are thought to harbor infections from early
childhood onwards that are either resolved, or become latent. Since macrophages are a key
host cell for cryptococcal infection, we sought to quantify the extent of individual variation in
this early phagocyte response within a small cohort of healthy volunteers with no reported
immunocompromising conditions. We show that rates of both intracellular fungal prolifera-
tion and non-lytic expulsion (vomocytosis) are remarkably variable between individuals.
However, we demonstrate that neither gender, in vitro host inflammatory cytokine profiles,
nor polymorphisms in several key immune genes are responsible for this variation. Thus
the data we present serve to quantify the natural variation in macrophage responses to this
important human pathogen and will hopefully provide a useful “benchmark” for the research
community.
Introduction
Cryptococcosis is the leading cause of fungal meningitis worldwide, with the vast majority of
clinical cases being caused by Cryptococcus neoformans. Pulmonary infection may begin when
yeast propagules are inhaled from the environment and engulfed by phagocytic cells patrolling
the lung epithelium. Most isolates of cryptococci are remarkably resistant to macrophage kill-
ing, and are able to adapt and survive within these myeloid cells causing latent infections that
may later disseminate upon immune suppression to cause cryptococcal meningoencephalitis
(CM) [1].
The last two decades have seen a decline in HIV-associated CM in developed countries due
to improved access to a combination of antiretroviral therapies and effective antifungal treat-
ments [2]. It has been estimated that 20% of global CM cases afflict non-HIV patients [3], with
more recent reports indicating a growing concern over CM due to C. neoformans in otherwise
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healthy individuals [2–4]. Despite the global distribution of this species, the highest frequency
of CM in immunocompetent individuals appears to come from South East Asia, with mortality
rates in China, Taiwan and Japan estimated to be at 17%, 70% and 35%, respectively [5–7]. In
the United States, recent epidemiological studies suggest the rate of cryptococcal infection
among non-HIV patients has risen significantly to match that in HIV-infected individuals [2,
8]. Whilst time to presentation following initial symptoms of infection does not differ between
HIV positive and negative patients [4], one of the issues restricting effective disease manage-
ment is that non-HIV CM patients represent a highly heterogenous group. In a retrospective
study that assessed predictors of disease mortality in different groups of cryptococcosis
patients, it was shown that it took an average of 68 days to diagnose otherwise healthy individ-
uals with cryptococcosis, while HIV patients were diagnosed within 22 days [9].
This may be due to differences in presentation of symptoms e.g. CM patients with HIV are
more likely to present with fever whilst the non-HIV group more frequently presents with
abnormal mental status, lung involvement and lesions in the central nervous system (CNS) [4]
or due to clinician awareness of cryptococcosis as a complication of HIV. Other studies have
shown that tools used to conventionally diagnose cryptococcosis differ in their specificity and
accuracy in detecting fungal load between HIV-patients and their healthy counterparts [10].
Treatment regimens for HIV-negative cryptococcosis patients are primarily based on data
from studies on HIV patients, due to the scarcity of data within a more relevant context [11].
Hence, an understanding of the host-pathogen interactions at a cellular level that enable ‘oth-
erwise healthy’ individuals to overcome cryptococcal disease would allow healthcare providers
more robust treatment strategies in this group, and ultimately improve survival rates.
Engulfed cryptococci are able to manipulate host phagosome maturation, enabling the
yeast’s intracellular survival [12, 13]. An interesting feature of Cryptococcus’s intracellular para-
sitism is its ability to undergo vomocytosis (non-lytic expulsion) from the host macrophage
either immediately or a few hours after engulfment [14, 15]. This rapid process has been sug-
gested to facilitate cryptococcal dissemination throughout the host whilst evading immune
detection, ultimately resulting in passage into the CNS via the Trojan horse model [16, 17].
Macrophages represent a key target cell for C. neoformans. Mice with depleted macrophages
infected with this pathogen showed enhanced survival over their wild type couterparts and sig-
nificantly lower CNS involvement [18]. Given that both latent and symptomatic infections
likely arise from an early intracellular, macrophage-associated, fungal colonization, a key ques-
tion is how variable this early macrophage response is to the fungus. Here we present quantita-
tive data from the in vitro challenge of monocyte-derived macrophages (MDMs) from 15
healthy individuals with C. neoformans var. grubii. Despite the relatively small cohort, there is
remarkable variation in macrophage ability to control both intracellular parasitism and vomo-
cytosis of C. neoformans. This variation is not easily explained either by variation in cytokine
signaling or genetic polymorphisms in several immune genes previously implicated in the
macrophage response to cryptococci and thus likely reflects either cryptic genetic variability
between donors or variation in the local environment experienced by the monocyte prior to in
vitro differentiation.
Materials and methods
Cryptococcus strains
C. neoformans var. grubii serotype A, strain KN99α [19] was used in all macrophage challenge
experiments. In order to obtain a fluorescently labeled strain suitable for imaging, the wild
type strain was biolistically transformed [20, 21] with a plasmid pAG32_GFP [20] encoding
for a green fluorescent protein (GFP) and subsequently validated for growth at 37˚C and 5%
Variation in macrophage responses to Cryptococcus neoformans
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CO2 and for sensitivity against several stress conditions mimicking the hostile environment
inside phagocytes (S1b and S1c Fig). After 24 hours of growth, serial dilutions of cells were
plated onto YPD plates and colony-forming units (CFU) counted. CFUs relative to time point
0, before stress treatment, were calculated.
In addition, GFP expressing transformants were tested for their survival and intracellular
proliferation rates (IPR) inside J774 macrophages. For IPR, 0.5 x 105 J774 cells were infected at
an MOI 1:10 with either wild type KN99α or GFP-expressing transformants (0.5 x 106 cells/
ml) opsonized with 18B7 antibody (a kind gift of Arturo Casadevall) as described previously
[20, 22]. The IPRs were assessed after initial 2 and following 24 hours of infection (S1a Fig).
Donor randomisation
This study was approved by the Science, Technology, Engineering and Mathematics Ethical
Review Committee of the University of Birmingham. Under ERN_15–0804, 30-60ml venous
blood samples were collected in lithium heparin VACUTAINER1 tubes obtained from
healthy volunteers with full informed consent, and randomized immediately after donation.
Due to unavailabity for repeat blood donations, RG008 was excluded from the study.
Serum collection
VACUTAINER1 tubes with silica bead clot activator (CAT) were used to collect serum during
each blood donation, and incubated at 37˚C, 5% CO2 for one hour prior to centrifugation at
800 x g for 10 minutes. Live serum aliquots were thereafter stored at -80˚C for cytokine
profiling.
Monocyte isolation, differentiation and culture
Primary peripheral blood monocytes (PBMCs) were isolated from fifteen healthy volunteers
by double gradient centrifugation using Percoll1 (Sigma-Aldrich, H4522). The dual gradient
was created by layering 6 ml of 1.098 g/ml Percoll1 (70.9% Percoll1, 19.1% H2O, 10% 1.5M
NaCl) underneath 1.079 g/ml Percoll1 (56.3% Percoll1, 33.7% H2O, 10% 1.5M NaCl); onto
which 6 ml of undiluted donor blood was layered on top of, and centrifuged for 8 minutes at
150 x g, followed by 10 minutes at 1200 x g with no brake, or acceleration. The top layer of
monocytes separated by the dual gradient were removed and added to Red Blood Cell (RBC)
lysis Buffer (1L–8.3g NH4Cl, 1g KHCO3, 0.04g Na2 EDTA 2H2O, 2.5g BSA) at a ratio of 1:3
and incubated for 3 minutes at room temperature with gentle mixing then spun at 400 x g for
6 minutes. The buffer was removed, and monocytes washed twice with 50 ml of PBS (Sigma-
Aldrich), and PBS supplemented with Ca+ and Mg++ at 4 ˚C (Sigma-Aldrich).
Isolated monocytes were thereafter resuspended in 1 ml adhesion media (RPMI 1640 with
L-glutamine; Thermo Fisher Scientific, supplemented with heat inactivated (56˚C for 30 mins)
5% pooled human AB serum; Sigma-Aldrich, and 100 U/ml streptomycin, 100 U/ml penicillin;
Sigma-Aldrich), counted on haemocytometer and then seeded into 48-well cell culture plates
at a concentration of 1x106 cells/well and incubated at 37˚C at 5% CO2. The supernatant was
removed 2 hours later, and replaced with differentiation media (adhesion media supplemented
with 5% pooled human AB serum; Sigma-Aldrich and 20 ng/ml human M-CSF). Subsequent
media replacements occurred on day 3 and day 6 post-isolation with adhesion media, and
serum-free adhesion media, respectively. Human monocyte derived macrophages (HMDMs)
were activated on day 7 with RPMI 1640 supplemented with 5% human AB serum (Sigma-
Aldrich), 100 U/ml streptomycin, 100 U/ml penicillin, 0.5 μg/ml human IFN-γ; ImmunoTools;
and 1 μg/ml E. coli LPS; Sigma-Aldrich) 24 hours before carrying out the phagocytosis assay.
Variation in macrophage responses to Cryptococcus neoformans
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Cryptococcus infection of HMDMs
An overnight culture of the yeast was started by inoculating 3 mL of YPD (10 g/L yeast
extract, 20 g/L bacteriological peptone, and 20 g/L glucose (Sigma-Aldrich) media, and incu-
bated on a rotor at 20 rpm at 25 ˚C, prior to conducting the phagocytosis assay. In prepara-
tion for phagocytosis, yeast cells were washed in PBS, counted on a haemocytometer, and
opsonized with 5% heat-inactivated human AB serum (Sigma-Aldrich). MDMs where then
infected with 1x106 yeast cells per well (MOI 10:1), and incubated at 37˚C, 5% CO2 for 2
hours; after which non-engulfed yeast cells were washed away using PBS, and serum-free
adhesion media was added to infected MDMs. At 0 (T0) and 18 (T18) hours post-infection,
extracellular yeast cells were washed away using PBS and macrophages containing yeast cells
were lysed in dH2O at 37 ˚C, 5% CO2 for 30 minutes. For live imaging to quantify vomocyto-
sis, hMDMs were washed at T0, fresh serum-free RPMI added to infection wells and taken
for imaging.
CFU counts
Serial dilutions of the lysate from the phagocytosis assay were prepared and plated onto growth
plates (2% YPD with 1% agar; Sigma-Aldrich) then incubated for 48 hours at 25˚C. Intracellu-
lar proliferation rates were measured by dividing the number of counting colony-forming
units per milliliter at T18 by those at T0.
Live cell imaging
All time lapse images were captured on a Zeiss Axio Observer Live cell-imaging microscope
enclosed within a humidified Okolab microscope chamber set at 37˚C, 5% CO2, a Hamamatsu
digital camera, LD Plan-Neofluar 20x/0.4 Korr Ph 2 M27 objective, 38 HE Green Flourescent
reflector, using Zen software (Zeiss). 217 frames (1 frame, every 5 minutes for 18 hours) were
taken from four different positions within each well to produce movies for manual analysis.
Vomocytosis was measured as the percentage of intracellular cryptococci expelled from mac-
rophages over the 18-hour period in all well positions.
Cytokine profiling
Cell culture supernatants collected from donor MDMs at T0 and at T18 previously stored at
-80 ˚C were thawed on ice in preparation for cytokine profiling. Initially, samples from 6
donors were probed for alternative or differential production of 27 human cytokines and che-
mokines using the Luminex Bio-plex (27-plex; Bio-Rad) which were then narrowed down to a
panel of 7 cytokines that had previously been associated with cryptococcosis in HIV patients
(IL-1β, IL-6, G-CSF, GM-CSF, IFN-γ, MCP-1 (MCAF), and TNF-α) due to inavailability of
data in non HIV patients. We incorporated these cytokines into a custom-made Bio-plex Pro
Human Cytokine 7-plex express assay for subsequent cytokine detection in 12 donors, in
accordance with the manufacturer’s protocol. The fold change in cytokines released by donor
MDMs was calculated by dividing the cytokine concentrations (pg/mL) at T18 by those at T0
for each donor. Correlation with matched vomocytosis and IPR data was carried out using the
Graphpad Prism 6 software.
Genotyping of small nucleotide polymorphisms
Consent for DNA analysis was obtained from 9 of the donors in this study. Genomic DNA
was extracted from whole blood using Promega’s Wizard genomic DNA extraction kit. All
primer sequences used to assess TLR2, Dectin-1 and ERK5 SNPs were designed by using the
Variation in macrophage responses to Cryptococcus neoformans
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NCBI/ Primer-BLAST tool and are presented in S4 Table. The PCR products for each primer
set were analyzed on a 1% agarose gel stained with Sybr Safe (Invivogen), and purified using
Qiagen’s QIAquick PCR Purification Kit. For sequencing, we used the cycle sequencing tech-
nology provided by Eurofins Genomics on an ABI 3730XL sequencer. The results were ana-
lyzed by using 4peaks software, version 1.8; and multiple sequence alignments were generated
using ClustalX, version 2.1.
Results
To compare intra-donor and inter-donor variation in macrophage responses to infection with
C. neoformans, we took repeated blood samples from a cohort of 15 healthy volunteers over a
period of 2 years, taking into account seasonal effects on host immunity. We derived macro-
phages in vitro with macrophage colony-stimulating factor (M-CSF), and then analysed both
intracellular fungal proliferation rates (IPR; Fig 1A) and the rate of non-lytic yeast expulsion
from within macrophages (Fig 1B). Intracellular proliferation rate varied dramatically between
and within donors (Fig 1A; S1 and S2 Tables) and consequently there was no significant differ-
ence in mean IPR between individual donors, suggesting that environmental variation (e.g. in
the inflammatory status of the donor at the time of donation) is a more significant driver of
variation in IPR than donor genetic background. In contrast, vomocytosis rate (calculated as
the proportion of cryptococcal cells expelled from donor MDMs over an 18-hour period) was
much less variable between repeat samples either within or between donors (p = 0.0820, one-
way ANOVA; Fig 1B).
Interestingly, although vomocytosis shows much greater donor consistency than IPR, there
is nonetheless a significant correlation between IPR and vomocytosis for individual samples
(Fig 1C; R square = 0.2501, P-value = 0.0005).
Host cytokine profile has previously been shown to impact strongly on the response to
cryptococcocal infection [23, 24]. We therefore wondered whether differences in the secreted
cytokine and chemokine milieu during in vitro culture may influence their subsequent
response to cryptococci. To test this, we quantified levels of seven cytokines and chemokines
(interferon-γ (IFN-γ), TNF-α, interleukin-1b (IL-1b), interleukin-6 (IL-6), MCP-1, G-CSF
and GM-CSF) in the media immediately following cryptococcal infection and again 18 hours
later.
We correlated them with measured IPRs (Fig 2) and vomocytosis rates for each donor (Fig
3 and S3 Table). Although cytokine levels varied dramatically between samples there was no
significant correlation with either vomocytosis or IPR. Whilst MCP-1 showed a significant
correlation with IPR (Spearman r = 0.4917; P-value = 0.0467), this result only just achieved
significance and was primarily driven by a single outlier and should therefore be interpreted
cautiously. Thus donor variation in autocrine inflammatory signaling during culture may con-
tribute to, but cannot fully explain, the observed differences in cryptococcal response.
Given the established enhanced risk of cryptococcosis in men [25], we tested whether gen-
der impacts on these macrophage responses in vitro. However, neither IPR nor vomocytosis
rate showed variation with donor gender in this cohort (Fig 4).
Lastly, several immune signaling pathways have previously been shown to impact on vomo-
cytosis/IPR [26]. In many cases, genes encoding key components of these pathways are known
to be polymorphic in the human population and we therefore tested whether polymorphisms
in three such genes (TLR2, dectin-1 or ERK5; S4 Table) may contribute towards the host vari-
ability that we report here. However, all of our tested donors carried the major allele for all of
these polymorphisms, indicating that at least these three genes are unlikely to explain the
detected variation in IPR and vomocytosis.
Variation in macrophage responses to Cryptococcus neoformans
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Fig 1. Variation in host responses to C. neoformans infections. (A) A measured intracellular proliferation rate (IPR)
for each donor showing median of at least 2 biological repeats each (median = 0.53, mean = 0.6307, SD = 0.5275 and
Coefficient of variation = 83.64%). (B) Variable rates of vomocytosis observed between and within donors showing
median of at least 2 biological repeats each (median = 41.11%, mean = 41.55%, SD = 15.53 and Coefficient of variation =
37.37%). (C) Correlation between intracellular parasitism and non-lytic expulsion events (R square = 0.2501, P-value =
0.0005). Each point on the graph represents data from a single blood donation. Since not all participants were available
to provide four repeat donations across the study period, the number of repeated samples varies from donor to donor.
https://doi.org/10.1371/journal.pone.0194615.g001
Variation in macrophage responses to Cryptococcus neoformans
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Fig 2. Correlation of fold changes in pro-inflammatory cytokines with IPR. Cytokines released over 18 hours were
correlated with intracellular proliferation rates of KN99α-GFP from donor MDMs for 13 donors. Linear regression
analysis revealed a significant association with e) MCP-1 (Spearman r = 0.4917; P-value = 0.0467); and no significant
associations with a) IFN-γ; b) TNF-α; c) IL-1b; d) IL-6; f) G-CSF; nor g) GM-CSF. Note that only data points that
crossed the detection threshold are shown hence not all graphs contain all data points. The fold change in cytokines
released by donor MDMs was calculated by dividing the cytokine concentrations (pg/mL) at T18 by those at T0 for
each donor.
https://doi.org/10.1371/journal.pone.0194615.g002
Variation in macrophage responses to Cryptococcus neoformans
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Fig 3. Correlation of pro-inflammatory cytokine profile from donor MDMs over 18-hours with non-lytic
expulsion (vomocytosis) of KN99α-GFP. Linear regression analysis revealed no significant associations in 13 donors
with a) IFN-γ; b) TNF-α; c) IL-1b; d) IL-6; e) MCP-1; f) G-CSF; nor g) GM-CSF. Note that only data points that
crossed the detection threshold are shown hence not all graphs contain all data points. The fold change in cytokines
released by donor MDMs was calculated by dividing the cytokine concentrations (pg/mL) at T18 by those at T0 for
each donor.
https://doi.org/10.1371/journal.pone.0194615.g003
Variation in macrophage responses to Cryptococcus neoformans
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Discussion
Previous attempts to characterize the differences in disease presentation and outcomes
between HIV positive and negative CM patients suggest that exacerbated immune responses
in otherwise healthy individuals contribute to the high mortality rates in non-HIV CM
patients [27]. In this study, we aimed to establish the parameters of variation in “otherwise
healthy” host macrophage interactions with Cryptococcus neoformans; placing a particular
focus on the intracellular pathogenicity and vomocytosis of this pathogen. Even within the
small cohort characterized here, it is clear that vomocytosis rates show significant intra-donor
variation. In contrast, the ability of macrophages to control cryptococcal intracellular prolifer-
ation is highly variable even between samples from the same donor, suggesting that thus-far
unidentified environmental factors impact strongly on this phenotype.
Levels of key inflammatory cytokines have been shown to impact strongly on cryptococcal
disease progression in HIV patients [23]. However, the data we present here shows that vary-
ing cytokine profile does not explain the in vitro variation in vomocytosis or IPR. Thus the in
vivo impact of cytokine profile on cryptococcosis most likely does not act at the level of single
macrophage/fungus interactions.
Lastly, we found no evidence for variation being driven by polymorphisms in three key
immune signaling genes: in TLR2 [28, 29], Dectin-1 [29, 30] and ERK5 [31, 32], suggesting
that the underlying basis for the variation we detect either lies elsewhere in the genome or
occurs at the level of environmental stimuli and not genetic polymorphism.
Ultimately, we hope that this study will help to define the parameters of the normal macro-
phage response to cryptococci and therefore prove useful both for subsequent analyses and for
exploring disease heterogeneity in non-HIV cryptococcosis patients.
Supporting information
S1 Fig. Validation of GFP-tagged KN99α in comparison to wild-type KN99α strain. (A) GFP
expressing strain shows no altered virulence in J774 macrophages with mean IPR (± Standard
Fig 4. Analysis of gender contribution to observed variation. Two-tailed t-tests revealed no significant differences in a) intracellular virulence of
KN99α-GFP (P-value = 0.9856); and b) non-lytic yeast expulsion from donor MDMs (P-value = 0.3181). Plot shows means, error bars are
representative of standard deviations and n.s. states for non significant.
https://doi.org/10.1371/journal.pone.0194615.g004
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Deviation) for KN99α (2.938 ± 0.5953) and KN99α_GFP (3.084 ± 1.064). The GFP expressing
strain also shows no altered response to the stress conditions B) NaCl; and C) H2O2; P-values
for Wilcoxon test shown on graph.
(TIFF)
S1 Table. Dates of blood donations for monocyte extraction from 15 study participants.
(PDF)
S2 Table. Intra-donor variation in monocyte-derived macrophage (MDM) responses to C.
neoformans infections in vitro; means and medians shown are of at least 2 biological
repeats per donor extrapolated from at least 2 technical repeats.
(PDF)
S3 Table. Correlation data for fold changes in detected cytokines with intracellular prolif-
eration rate (IPR) and vomocytosis (%) of KN99α-GFP from MDMs from 13 healthy
donors.
(PDF)
S4 Table. Details of small nucleotide polymorphisms and primers analyzed in 9 healthy
donors.
(PDF)
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